These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35991721)

  • 1. Dermatomal rash after Shingrix vaccination: cause or coincidence?
    Mittal N; Dhir N; Mittal N
    Proc (Bayl Univ Med Cent); 2022; 35(5):686-687. PubMed ID: 35991721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of Herpes Zoster After Recombinant Vaccine (Shingrix): A Case Report.
    Altukhaim F; Mutlaq M; Alghamdi M; Hakami S
    Cureus; 2023 Jan; 15(1):e34431. PubMed ID: 36874700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.
    Sly JR; Harris AL
    Nurs Womens Health; 2018 Oct; 22(5):417-422. PubMed ID: 30145235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shingrix for Herpes Zoster: A Review.
    Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children.
    Moodley A; Swanson J; Grose C; Bonthius DJ
    J Child Neurol; 2019 Mar; 34(4):184-188. PubMed ID: 30628536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Zoster disease after Shingrix vaccination].
    Kohn D; Wetzig T
    Hautarzt; 2021 Aug; 72(8):729-732. PubMed ID: 33294953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
    Izurieta HS; Wu X; Forshee R; Lu Y; Sung HM; Agger PE; Chillarige Y; Link-Gelles R; Lufkin B; Wernecke M; MaCurdy TE; Kelman J; Dooling K
    Clin Infect Dis; 2021 Sep; 73(6):941-948. PubMed ID: 33580242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection.
    Alexander KE; Tong PL; Macartney K; Beresford R; Sheppeard V; Gupta M
    Vaccine; 2018 Jun; 36(27):3890-3893. PubMed ID: 29807711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review.
    Bell H; Kamal N; Wong U
    Vaccine; 2020 Nov; 38(47):7455-7457. PubMed ID: 33067034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K; Weinberg JM
    J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Characterization of CD4
    Voic H; de Vries RD; Sidney J; Rubiro P; Moore E; Phillips E; Mallal S; Schwan B; Weiskopf D; Sette A; Grifoni A
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute retinal necrosis following recombinant subunit varicella-zoster virus vaccine.
    Chen RI; Deaner JD; Srivastava SK; Lowder CY
    Am J Ophthalmol Case Rep; 2020 Dec; 20():100962. PubMed ID: 33163688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of herpes zoster (shingles) and postherpetic neuralgia.
    Stankus SJ; Dlugopolski M; Packer D
    Am Fam Physician; 2000 Apr; 61(8):2437-44, 2447-8. PubMed ID: 10794584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Herpes Zoster Radiculopathy of the Lower Extremity With Dermatomal Rash and Lumbar Nerve Enhancement on MRI.
    Bhushan S; Dominguez L; Shirazi E; Gupta V
    Mayo Clin Proc Innov Qual Outcomes; 2020 Oct; 4(5):608-610. PubMed ID: 33083710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.
    Liesegang TJ
    Ophthalmology; 2008 Feb; 115(2 Suppl):S3-12. PubMed ID: 18243930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide.
    Guillo L; Rabaud C; Choy EH; D'Amico F; Danese S; Ng SC; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):481-490. PubMed ID: 33080353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine.
    Thompson H; Nichols L; Gonzalez Santiago T
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34413031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.